Back to MORGAN STANLEY MORGAN STANLEY

CYCNCYCN
Showing 8 of 9 quarters

Position history for MORGAN STANLEYMORGAN STANLEY's holdings in CYCLERION THERAPEUTICS INC

No. Morgan Stanley exited its CYCN (Cyclerion Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 1 shares worth $2. Morgan Stanley already held CYCN in its Q2 2024 13F, the earliest on record, and held it in 8 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$1,681

Total Shares Change

-649

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$3.39
0
2026-Q1
Unchanged
1
0.0%
$20.0%$1.35
0
2025-Q4
Decreased
1
-99.8%
$20.0%$1.18
0
2025-Q3
Unchanged
649
0.0%
$1,4930.0%$2.34
0
2025-Q2
Unchanged
649
0.0%
$1,8890.0%$3.00
0
2025-Q1
Unchanged
649
0.0%
$1,6230.0%$2.57
0
2024-Q4
Unchanged
649
0.0%
$2,0900.0%$22.54
0
2024-Q3
Unchanged
649
0.0%
$1,6810.0%$18.13
0

Other major holders of CYCN: FMR LLC, BALYASNY ASSET MANAGEMENT L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used